Dirk Otto, the general manager of Boehringer Ingelheim Australia and New Zealand, said, “Thousands of Australians face the very real prospect of kidney replacement therapy or serious cardiovascular complications without timely treatment to protect kidney function."
TGA approves new indication for BI-Lilly alliance SGLT-2 inhibitor
February 22, 2024 Latest NewsBioPharma![](https://e76bb9fd1f54a7a912eb-40f6ec802f763655ee14c32dfe77820e.ssl.cf4.rackcdn.com/f1e2610078f0c3fc01b3db262df6e40f.jpg)
Latest Video
New Stories
-
The 'Week in Review' Podcast - 26 July
July 26, 2024 - - Podcast -
'We approached stakeholders that were highly engaged with the HTA review process'
July 26, 2024 - - Latest News -
Preaching transparency and not practising it is the worst possible look
July 26, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
New large study shows vaccination halves the risk of patients suffering Long-COVID
July 25, 2024 - - Latest News -
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News